Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort-Reference-Cited by-同舟云学术

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort

Published:2019-01 Issue:1 Volume:22 Page:e25227
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Intern AIDS Soc

Author:

Mondi Annalisa¹^ORCID,Cozzi‐Lepri Alessandro²,Tavelli Alessandro³,Rusconi Stefano⁴,Vichi Francesca⁵,Ceccherini‐Silberstein Francesca⁶,Calcagno Andrea⁷,De Luca Andrea⁸,Maggiolo Franco⁹,Marchetti Giulia¹⁰,Antinori Andrea¹,d'Arminio Monforte Antonella¹⁰,Andreoni M,Castagna A,Castelli F,Cauda R,Di Perri G,Galli M,Iardino R,Ippolito G,azzarin A,Rezza G,Schloesser F,Viale P,Ceccherini‐Silberstein F,Cozzi‐Lepri A,Girardi E,Lo Caputo S,Mussini C,Puoti M,Perno CF,Balotta C,Bandera A,Bonora S,Borderi M,Capetti A,Capobianchi MR,Cicalini S,Cingolani A,Cinque P,Di Biagio A,Gianotti N,Gori A,Guaraldi G,Lapadula G,Lichtner M,Madeddu G,Maggiolo F,Monno L,Nozza S,Quiros Roldan E,Rossotti R,Rusconi S,Santoro MM,aracino A,Sarmati L,Fanti I,Galli L,Lorenzini P,Rodano’ A,Macchia M,Tavelli A,Carletti F,Carrara S,Di Caro A,Graziano S,Petrone F,Prota G,Quartu S,Truffa S,Giacometti Italy A,Costantini A,Barocci V,Angarano G,Fabrizio C,Suardi C,i V,Verucchi G,Castelnuovo F,Minardi C,Menzaghi B,Abeli C,Cacopardo B,Celesia B,Vecchiet J,Falasca K,Pan A,Lorenzotti S,Sighinolfi L,Segala D,Blanc P,Cassola G,Viscoli C,lessandrini A,Bobbio N,Mazzarello G,Pozzetto I,Bonfanti P,Molteni C,Chiodera A,Milini P,Nunnari G,Pellicanò G,Rizzardini G,Bai F,Moioli MC,Piolini R,Ridolfo AL,Salpietro S,Tincati C,Puzzolante C,Migliorino C,Sangiovanni V,Borgia G,Esposito V,Di Martino F,Gentile I,Maddaloni L,Cattelan AM,Marinello S,Cascio A,Colomba C,Baldelli F,Schiaroli E,Parruti G,Sozio F,Magnani G,Ursitti MA,Cristaudo A,Vullo V,Acinapura R,Baldin G,Capozzi M,Rivano Capparucia M,Iaiani G,atini A,Mastrorosa I,Plazzi MM,Savinelli S,Vergori A,Cecchetto M,Viviani F,Bagella P,Rossetti B,Fontana Del Vecchio R,Francisci D,Di Giuli C,Caramello P,Orofino GC,Sciandra M,Bassetti M,ondero A,Pellizzer G,Manfrin V,Starnini G,alungo A,

Affiliation:

1. HIV/AIDS Department National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS Rome Italy

2. Institute for Global Health University College London London UK

3. Icona Foundation Milan Italy

4. Infectious Diseases Unit ASST FBF‐Sacco, DIBIC “L. Sacco” University of Milan Milan Italy

5. Unit of Infectious Diseases Santa Maria Annunziata Hospital Firenze Italy

6. Department of Experimental Medicine and Surgery University of Rome Tor Vergata Rome Italy

7. Unit of Infectious Diseases Department of Medical Sciences Amedeo di Savoia Hospital University of Torino Turin Italy

8. Infectious Diseases Unit University of Siena Siena Italy

9. Unit of Infectious Diseases ASST‐PG23 Bergamo Italy

10. Clinic of Infectious and Tropical Diseases Department of Health Sciences ASST Santi Paolo e Carlo University of Milan Milan Italy

Funder

ViiV Healthcare

Gilead Sciences

Bristol-Myers Squibb

Merck Sharp and Dohme

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25227

Reference30 articles.

1. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV‐1‐infected adults and adolescents.Department of Health and Human Services;2017. [cited 12 Dec 2017]. Available from:https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf

2. World Health Organization.Updated recommendations on first‐line and second‐line antiretroviral regimens and post‐exposure prophylaxis and recommendations on early infant diagnosis of hiv. HIV treatment‐interim guidance. [cited 11 Oct 2018]. Available from:http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-eng.pdf?ua=1

3. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

4. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

5. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active HIV infection and current effectiveness rate of dolutegravir-based treatment among people living with HIV in Gabon;2024-06-25

2. Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study;Cureus;2024-06-17

3. Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study;Heliyon;2024-06

4. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana;Viruses;2024-05-01

5. Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy;Antioxidants;2024-04-26